- Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47–66 (2024).
Article
PubMed
Google Scholar
2. Fu, Q. et al. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine 63, 102175 (2023).
Article
PubMed
PubMed Central
Google Scholar
3. Shi, D. et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin. Cancer Res. 26, 3979–3989 (2020).
Article
CAS
PubMed
Google Scholar
4. Du, G. et al. Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy. Front. Immunol. 15, 1431211 (2024).
Article
CAS
PubMed
PubMed Central
Google Scholar
5. Giardino Torchia, M. L. et al. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. Cytotherapy 24, 720–732 (2022).
Article
CAS
PubMed
Google Scholar
6. Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589–604 (2019).
Article
PubMed
PubMed Central
Google Scholar
7. Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
Article
CAS
PubMed
Google Scholar
8. Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).
Article
PubMed
Google Scholar
9. Rizzo, A. \& Brandi, G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat. Res. Commun. 27, 100328 (2021).
PubMed
Google Scholar
10. Wang, Y. et al. Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp. Hematol. Oncol. 10, 45 (2021).
[Article](https://link.springer.com/doi/10.1186/s40164-021-00237-y)
[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34399826)
[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365942)
[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20plus%20bevacizumab%20combination%20enables%20an%20unresectable%20hepatocellular%20carcinoma%20resectable%20and%20links%20immune%20exclusion%20and%20tumor%20dedifferentiation%20to%20acquired%20resistance&journal=Exp.%20Hematol.%20Oncol.&doi=10.1186%2Fs40164-021-00237-y&volume=10&publication_year=2021&author=Wang%2CY)
-
Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325–332 (2022).
Article
CAS
PubMed
Google Scholar
12. Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).Article
CAS
PubMed
Google Scholar
13. Shin, M. H. et al. Recent advances in CAR-based solid tumor immunotherapy. Cells 12, 1606 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
14. Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940–946 (2025).Article
ADS
CAS
PubMed
Google Scholar
15. Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 405, 2049–2060 (2025).Article
CAS
PubMed
Google Scholar
16. Ning, S. et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol. Biol. Rep. 39, 351–357 (2012).Article
CAS
PubMed
Google Scholar
17. Guo, M., Zhang, H., Zheng, J. \& Liu, Y. Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma. J. Cancer 11, 2008–2021 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
18. Giardino Torchia, M. L. \& Moody, G. DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies. Front. Immunol. 14, 1264882 (2023).Article
PubMed
PubMed Central
Google Scholar
19. Tauriello, D. V. F., Sancho, E. \& Batlle, E. Overcoming TGFβ-mediated immune evasion in cancer. Nat. Rev. Cancer 22, 25–44 (2022).Article
CAS
PubMed
Google Scholar
20. An, Y. et al. Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma. World J. Gastroenterol. 24, 2733–2740 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
21. Shirai, Y. et al. Plasma transforming growth factor-β 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73, 2275–2279 (1994).Article
CAS
PubMed
Google Scholar
22. Narayan, V. et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724–734 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
23. Park, B. V. et al. TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. 6, 1366–1381 (2016).Article
CAS
PubMed
PubMed Central
Google Scholar
24. Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
25. Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).Article
CAS
PubMed
Google Scholar
26. Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282–296 (2019).Article
CAS
PubMed
Google Scholar
27. Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).Article
CAS
PubMed
Google Scholar
28. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).Article
CAS
PubMed
Google Scholar
29. Sun, L. et al. Shed antigen-induced blocking effect on CAR-T cells targeting glypican-3 in hepatocellular carcinoma. J. Immunother. Cancer. 9, e001875 (2021).Article
PubMed
PubMed Central
Google Scholar
30. Ren, Z. et al. Sintilimab plus bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomized, open-label, phase 2-3 study. Lancet 22, 977–990 (2021).